A new CAR-T is credited with a 'surprising' impact in tiny study of advanced liver cancer — raising hopes on solid tumors
A tiny study has provided the first glimmer of hope that Eureka Therapeutics’ CAR-T therapy may work in solid tumors.
In a proof-of-concept study involving six patients with hepatocellular carcinoma — the most prevalent form of liver cancer — researchers reported that one patient had a complete response, which was maintained at the seven-month checkup. Two others saw their tumors shrink.
These, the biotech emphasizes, are patients who have failed multiple prior treatments.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters